Looking for a job

Donald Darby

@donalddarby

Investor relations consultant at LaVoieHealthScience who led investor relations for crossover funding and pre-IPO activities for a commercial-ready treatment.

United States

Message

At LaVoieHealthScience, I provide investor outreach and strategic messaging, positioning, and counsel to executive management for clients. I led investor relations for crossover funding and pre-IPO activities for a commercial-ready Presbyopia treatment.

At BioMarin Pharmaceutical, Inc., I created a new earnings structure and materials, including modeling for 27 analysts, as the company became profitable in 2023. I also developed the company’s first model to monitor investment-community earnings projections and share analysis with senior management.

I conducted BioMarin’s 2023 and 2024 Investor Day in New York City and navigated communications around FDA approval of ROCTAVIAN, VOXZOGO label expansions, R&D Day, an activist shareholder, and executive appointments.

Earlier, at Assertio Therapeutics, Inc., I supported the company’s rebrand and NASDAQ relisting and created a new investor relations website. At Horizon Pharma Plc, I developed communications for three acquisitions and participated in raising over $700 million in debt to fund the acquisition of Raptor Pharmaceuticals.

Experience

Work history, roles, and key accomplishments

Current

Senior Consultant, Strategic Communications and Investor Relations

Current

LaVoieHealthScience

Jan 2025 - Present (1 year 9 months)

Provided proactive outreach to prospective and existing investors for clients including strategic messaging, positioning, strategy and counsel to executive management. Led investor relations for crossover funding and pre-IPO activities for commercial-ready Presbyopia treatment.

Investor Relations Strategic Communications Messaging Positioning Strategy Executive Legal Counsel Crossover Funding Pre IPO

Director, Investor Relations

BioMarin Pharmaceutical, Inc.

Jan 2022 - Dec 2024 (2 years 11 months)

Initiated many first processes as the Company became profitable in 2023; created new earnings structure, standard operating procedures, presentations, supplemental workbooks and modeling for 27 analysts. Targeted and courted large institutional investors for initial and re-investment, and conducted global investor targeting with execution through non-deal road shows, investor conferences, conferen

Investor Relations Financial Modeling Earnings Calls Investor Targeting Roadshows Investment Conferences FDA Regulatory Communications Investor Communications Sell Side Financial Communications

Director, Investor Relations and Corporate Communications

LifeSci Advisors LLC

Jan 2021 - Dec 2022 (1 year 11 months)

Served as senior investor relations counsel to multiple public companies. Responsibilities included counsel for investor communications deliverables, creating awareness with institutional investors, attracting sell side coverage, KOL events, earnings releases, press releases, presentations, up-listing to major exchanges and high level investor engagement.

Investor Relations Corporate Communications Investor Awareness Supply Side Coverage KOL Event Planning Earnings Releases Press Releases Uplisting Investor Engagement

Director, Finance, Investor Relations and Corporate Communications

Assertio Therapeutics, Inc.

Jan 2018 - Dec 2021 (3 years 11 months)

Rebranded and relisted on NASDAQ, previously Depomed (DEPO) Inc. to Assertio Therapeutics (ASRT). Included all start-up deliverables: website, logos, presentations, identity, missions, investor outreach, shareholder approval among many other start-up related activities. Led change management initiatives and completed merger with Zyla Life Sciences.

Investor Relations Corporate Communications Rebranding Nasdaq Listing Standards Change Management Post Merger Integration Financial Communications Board Reporting Market Intelligence Vendor Management

Senior Manager, Investor Relations and Corporate Communications

Horizon Pharma Plc

Jan 2015 - Dec 2018 (3 years 11 months)

Reported to SVP of Strategy and IR, lead on all written materials related to earnings, acquisitions, financial communications (presentations, scripts, press releases, Q&A and executive coaching and preparation documents for senior management). Successfully completed three accretive acquisitions: Crealta Pharmaceuticals, Raptor Pharmaceuticals and Phase III candidate, teprotumumab.